Comparing Adjuvant Immunotherapy vs Targeted Therapy in Stage III BRAF -Mutant Melanoma

Publication date: Jun 26, 2025

This is true both for targeted therapy and for immunotherapy. Why is this relapse-free survival analysis so important and why did we do this comparison? First, because these two therapies are approved for patients who have a BRAF mutation and there are no head-to-head comparisons that have been performed in clinical trials. We were able to include more than 3000 patients with a median follow-up that goes between 11 and 33 months. Approximately half of the patients, 57%, had a BRAF mutation. The first analysis we performed was in terms of relapse-free survival. What kind of therapy in the adjuvant setting should we give to these patients? To address this question, we have recently published a review in terms of real-world data comparing these two therapies. Why did we do that? After the first review, we had 29 publications, excluding the duplicates.